Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis Patients, Single-Center, Prospective, Open-Label, Single-Arm Clinical Trial, Long-Term Follow-up

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

NABAVI SEYED MASSOOD; Karimi Shahedeh; ARAB LEILA; SANJARI LEILA; MARDPOUR SOURA; AZIMIAN VAJIHEH; Jarughi Neda; GHAHERI AZADEH; HOSSEINI SEYEDEH ESMAT; AGHDAMI NASSER; VOSOUGH MASSOUD

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Cell Journal (Yakhteh) Year:2021 | Volume:23 | Issue:7 Page(s): 772-778

Download Full-Text

View:

130

Download:

113

Cites:

Information Journal Paper

Title

Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis Patients, Single-Center, Prospective, Open-Label, Single-Arm Clinical Trial, Long-Term Follow-up

Author(s)

Keywords

Allogeneic Cells

Amyotrophic Lateral Sclerosis

Autologous Cell Transplantation

Mesenchymal Stromal Cells

Stem Cells

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder with very limited treatment options. Stem Cells have been raised as a new treatment modality for these patients. We have designed a single-center, prospective, open-label, and single arm clinical trial to assess the safety, feasibility, and rather efficacy of administrating allogeneic adipose-derived Mesenchymal Stromal Cells (Ad-MSCs) in ALS patients. We enrolled 17 patients with confirmed ALS diagnosis with ALS Functional Rating Scale-Revised (ALSFRS-R) ≥ 24 and predicted forced vital capacity (FVC) ≥ 40%. Allogeneic Ad-MSCs were transplanted intravenously for all patients. Follow-ups were done at 24 hours, 2, 4, 6, and 12 months after cell infusion by checking adverse events, laboratory tests, and clinically by ALSFRS-R and FVC. Patients were also followed five years later and ALSFRS-R score was recorded in the survived individuals. There was no report of severe adverse events related to cell infusion. Two patients experienced dyspnea and chest pain 36 and 65 days after cell infusion due to pulmonary emboli. The progressive decrease in ALSFRS-R and FVC levels was recorded and three patients died in the first year. During five years follow up, despite a notable decrease in functional scores, 5 patients survived. Intravenous (IV) infusion of allogeneic Ad-MSCs in ALS patients is safe and feasible. The survival rate of the patients is more than IV autologous MSCs (Registration number: IRCT20080728001031N26).

Multimedia

No record.

Cites

No record.

References

No record.

Cite

APA: Copy

NABAVI, SEYED MASSOOD, Karimi, Shahedeh, ARAB, LEILA, SANJARI, LEILA, MARDPOUR, SOURA, AZIMIAN, VAJIHEH, Jarughi, Neda, GHAHERI, AZADEH, HOSSEINI, SEYEDEH ESMAT, AGHDAMI, NASSER, & VOSOUGH, MASSOUD. (2021). Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis Patients, Single-Center, Prospective, Open-Label, Single-Arm Clinical Trial, Long-Term Follow-up. CELL JOURNAL (YAKHTEH), 23(7), 772-778. SID. https://sid.ir/paper/692150/en

Vancouver: Copy

NABAVI SEYED MASSOOD, Karimi Shahedeh, ARAB LEILA, SANJARI LEILA, MARDPOUR SOURA, AZIMIAN VAJIHEH, Jarughi Neda, GHAHERI AZADEH, HOSSEINI SEYEDEH ESMAT, AGHDAMI NASSER, VOSOUGH MASSOUD. Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis Patients, Single-Center, Prospective, Open-Label, Single-Arm Clinical Trial, Long-Term Follow-up. CELL JOURNAL (YAKHTEH)[Internet]. 2021;23(7):772-778. Available from: https://sid.ir/paper/692150/en

IEEE: Copy

SEYED MASSOOD NABAVI, Shahedeh Karimi, LEILA ARAB, LEILA SANJARI, SOURA MARDPOUR, VAJIHEH AZIMIAN, Neda Jarughi, AZADEH GHAHERI, SEYEDEH ESMAT HOSSEINI, NASSER AGHDAMI, and MASSOUD VOSOUGH, “Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis Patients, Single-Center, Prospective, Open-Label, Single-Arm Clinical Trial, Long-Term Follow-up,” CELL JOURNAL (YAKHTEH), vol. 23, no. 7, pp. 772–778, 2021, [Online]. Available: https://sid.ir/paper/692150/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops